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Abstract 
The aim of this paper is to compare results from inhalation studies with those from intraperitoneal 
and intrapleural tests, where available, for a number of fibrous and particulate test materials. The 
objective is to determine how well intraperitoneal/intrapleural studies predict the pathological 
responses observed in more standard in vivo studies of pulmonary toxicity, with a particular focus on 
carcinogenicity. 
Published toxicity data was obtained for a number of materials including asbestos, wollastonite, 
MMVFs (including glass fibres, stone wools and RCF), silicon carbide whiskers, potassium 
octatitanate, quartz, kevlar, polypropylene and titanium dioxide.  
 
For some of the fibrous material reviewed, there is conformity between the results of 
intraperitoneal and inhalation tests such that they are either consistently positive or consistently 
negative. For the remaining fibrous materials reviewed, intraperitoneal and inhalation tests give 
different results, with positive results in the intraperitoneal test not being reflected by positive 
inhalation results.  
 
It is suggested that the intraperitoneal test can be used to exonerate a dust or fibre (because if 
negative in the intraperitoneal test it is extremely unlikely to be positive in either inhalation or 
intratracheal tests) but should not be used to positively determine that a dust or fibre is carcinogenic 
by inhalation. We would argue against the use of intraperitoneal tests for human health risk 
assessment except perhaps for the purpose of exoneration of a material from classification as a 
carcinogen. 
 
Key Words: intra-pleural; intra-peritoneal; inhalation; intra-tracheal; dusts; fibres; 
pathological response; carcinogenic response; pulmonary toxicity; in vivo. 
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1. Introduction 1 
Hazard characterisation of the toxicity and carcinogenic potential of airborne dusts and fibres is 2 
usually carried out using in vivo test methods, although in vitro approaches are increasingly being 3 
utilised to investigate specific relevant toxicological parameters. The in vivo models used include 4 
inhalation (IH; whole body or nose-only), intratracheal instillation (IT), intraperitoneal injection (IP) 5 
and intrapleural injection (IPl). The intratracheal test essentially aims to replicate exposure by 6 
inhalation, while intraperitoneal/ intrapleural injection tests investigate the toxicity of fibres to the 7 
mesothelium and have also been used to assess carcinogenic potency. As explained more fully 8 
below, although expensive to conduct, inhalation toxicity studies are still generally viewed as the 9 
‘gold standard’ for airborne dusts and fibres (McLellan et al., 1992; Pauluhn & Mohr, 2000).  10 
 11 
The toxicity of inhaled fibres is described by the so called ‘3Ds’ paradigm which recognises that the 12 
most important parameters are dose, dimension (fibre length and diameter, which determine both 13 
respirability and pathogenicity in the lung) and durability (or, more properly, biopersistence) 14 
(Bernstein et al., 2001a; Bernstein et al., 2001b; Brown & Harrison, 2012; Donaldson et al., 2013). 15 
For dusts (rather than fibres) the fundamental concerns are fibrogenicity and cancer due either to 16 
inherent pulmonary toxicity or to lung overload effects (Oberdorster, 1995; Pauluhn, 2014; Borm et 17 
al., 2015; Morfeld et al., 2015).  18 
 19 
The heterogeneity of toxic responses to fibres at different locations in the respiratory tract has been 20 
described, for example, by Donaldson et al. (2013) using the well documented example of asbestos. 21 
The principal pathologies are as follows: 22 
 23 
• Lung parenchyma – interstitial fibrosis with accumulation of fibrous/scar tissue; 24 
• Bronchi/bronchioles – bronchogenic carcinoma (malignant cancer of the cells lining the 25 
airways); 26 
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• Pleurae (visceral and parietal surfaces) – pleural fibrosis (diffuse accumulation of scar tissue 27 
in the pleura) and mesothelioma (malignant tumour arising from the mesothelium lining the 28 
pleural space); 29 
• Parietal pleura – pleural plaque (deposits of hyalinised collagen fibres).  30 
 31 
As all inhaled fibres and dusts are not equally pathogenic, only some, or possibly none, of these 32 
effects will arise following inhalation of any particular material. In this paper the end-point of 33 
particular interest is cancer of the lung and/or mesothelium. 34 
 35 
This review aims to compare findings from inhalation studies with those using the same fibrous or 36 
particulate test materials delivered by the intraperitoneal or intrapleural injection routes. The 37 
specific objective is to assess how well intraperitoneal/intrapleural injection studies can predict the 38 
pathological responses to airborne dusts and fibres that are observed in inhalation studies of 39 
pulmonary toxicity, in particular with respect to carcinogenicity. Where intratracheal studies have 40 
also been carried out, these are included for completeness; however, for reasons detailed below 41 
(Section 3) for some materials the intratracheal test may not be particularly informative regarding 42 
cancer endpoints.  43 
 44 
It is emphasised that this review is not intended to be an exhaustive collection of all published 45 
studies, but rather a focused comparison of inhalation and IP/IPl test data for a range of dusts and 46 
fibres. A good understanding of this relationship is important because of the continued use by some 47 
jurisdictions of IP test results for human cancer risk assessment (Harrison et al., 2015).  48 
 49 
2. Inhalation methods 50 
 51 
The overall aim of an IH study is to administer a well characterised exposure concentration that can 52 
be related to inhaled dose and any subsequent response in the animal (Wong, 2007). Inhalation 53 
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studies can, however, be subject to variability in several areas including: animals’ environment and 54 
surroundings; exposure atmosphere; the applied dose; and individual animal biological sensitivity. 55 
High degrees of standardisation and control are therefore required to make test results reproducible 56 
and comparable, and to fulfil general regulatory requirements (Pauluhn and Mohr, 2000).  57 
 58 
Systems have been developed to provide a uniform, controlled environment for inhalation studies 59 
for all types of experimental animals in terms of temperature, humidity, air flow, oxygen content, 60 
and other major environmental factors (Wong, 2007).  Exposure techniques include whole-body 61 
chambers, and head and nose-only chambers, which are described briefly below. 62 
 63 
Whole-body chambers: In these the animal is immersed in the atmosphere of the chamber. This 64 
approach has the advantage of simulating ‘natural’ workplace or environmental exposures with 65 
unrestrained animals. It is the most efficient approach for testing large numbers of animals and/or 66 
for long duration studies as the animals can be housed in the chambers. However, this approach 67 
uses a large amount of material, and good air mixing in the chamber is essential. In addition, co-68 
exposure through oral and dermal routes cannot be excluded. 69 
 70 
Head and nose-only chambers: In these the animal is restrained so that only the head or nose is 71 
exposed to the test material. This has the advantage that co-exposure through other routes is 72 
unlikely and less material is needed. Additionally, it is easier to contain the test material and allows 73 
flexibility in removing animals without the rest of the test group being affected. Disadvantages of 74 
this approach include stressing the animals during restraint, and lack of food and water during the 75 
exposure period.   76 
 77 
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3. Pulmonary deposition methods 78 
These alternative methods act as surrogates for inhalation testing and allow instantaneous delivery 79 
of a precise dose of test material suspended in a small volume of vehicle to the lungs.  As the 80 
material is delivered directly to the lower respiratory tract, the potential for deposition in the nasal 81 
passsages and/or on fur that can occur in nose-only or whole-body inhalation exposure systems is 82 
avoided (Osier & Oberdörster, 1997). Pulmonary deposition methods include the following: 83 
Intratracheal Instillation (IT): This much used technique deposits a precise dose (bolus) of material 84 
into the lungs, although the test substance may not be distributed in and cleared from the lungs in 85 
the same way as would occur via nose-only inhalation. Intratracheal instillation has been used for 86 
repeated dose studies, for example to test carcinogenicity and establish relative potency of fibrous 87 
and non-fibrous particulates (Pott, 1993 – cited by Wong, 2007), and to evaluate particulate material 88 
that is not readily inhaled by rodents (Driscoll et al., 2000 – cited by Wong, 2007). However, as this 89 
technique usually involves a course of injections over a period of several weeks (only) it cannot 90 
strictly be considered a 'chronic' exposure as would be achieved in a 24 month IH study; thus for 91 
materials with low biopersistence the IT test may not be especially informative regarding the cancer 92 
endpoint (Driscoll et al., 2000 – cited by Wong, 2007).  93 
Oropharyngeal Aspiration: This deposits a specific dose of material on the base of the animal’s 94 
tongue which is then aspirated into the lungs during inhalation. This has the advantage over 95 
intratracheal instillation in that material is distributed throughout the lungs, however Foster et al. 96 
reported that the clearance of material from the lungs is altered from nose-only inhalation (Foster et 97 
al., 2001 – cited in Wong, 2007). 98 
• Endotracheal Inhalation: This method utilises a tight-fitting catheter inside the animal’s 99 
trachea to inflate the lungs, during which the test material is delivered. This has been used to 100 
assess ultrafines and non-inhalable aerosols (Oberdorster et al., 1995 – cited in Wong, 2007).   101 
• Tracheostomy: A surgical opening in the trachea allows delivery of the test material via a 102 
cannula. This method can also be used to obtain fluid or cells from the lungs. 103 
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 104 
The disadvantages of such techniques is that animals require anaesthesia (and, for some, surgical 105 
procedures), making then unsuitable for long-term repeat-dose studies. In addition, normal 106 
defensive mechanisms are by-passed. 107 
 108 
4. Intracavity injection methods 109 
In addition to the inhalation and pulmonary deposition methods, two other routes of administration 110 
have become commonly associated with toxicological assessment of airborne dusts and fibres, 111 
namely intrapleural and, especially, intraperitoneal injection.   112 
4.1 Intrapleural injection (IPl) 113 
The most relevant intracavity method for the assessment of pleural toxicity involves delivery of the 114 
test material directly into the pleural space (Murphy et al., 2011).  This model has been validated for 115 
studying pre-mesothelioma processes, for example (Wagner, 1984). Unfortunately it is a technically 116 
difficult procedure, as the injection needle has to be positioned exactly within the pleural space, and 117 
there are associated ethical issues; these factors limit its use for routine testing purposes. 118 
4.2 Intraperitoneal injection (IP) 119 
Use of the peritoneal cavity as a model for the assessment of fibre pathogenesis has been well 120 
documented for many fibre types including asbestos, synthetic vitreous fibres and nanofibres 121 
(Donaldson et al., 2013). As the pleural space has, at least until recently, been difficult to utilise 122 
directly for toxicity testing due to technical issues associated with effective delivery of test material 123 
(see 4.1 above), injection directly into the peritoneal cavity, which is also lined with mesothelium, 124 
has proved an accessible and viable alternative. As with the pleural cavity, fibres or particles 125 
introduced into the peritoneal cavity which cannot pass through the mesothelial stomata will be 126 
retained, potentially leading to a pathogenic response (Donaldson et al., 2010).  127 
 128 
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Advantages of the intrapleural method include: use of a small amount of test substance, ease of 129 
delivering the same dose to all animals, reduced cost, and in some respects a more ‘sensitive’ test in 130 
comparison to inhalation methods (Miller et al., 1999). However, certain important limitations also 131 
need to be considered: 132 
• The natural filtering and clearance mechanisms of the lung are by-passed, meaning 133 
that material is injected that might never reach the pleura following inhalation 134 
exposure; 135 
• High doses are delivered at high rates, contrary to that occurring in the pleura under 136 
normal physiologic conditions;  137 
• Impacts on the airways and lung parenchyma are not investigated; 138 
• The impact of fibre biopersistence during transit from the deposition site to the 139 
pleura is not taken into account; 140 
• The influence of fibre diameter on pulmonary uptake and deposition is not taken 141 
into account; 142 
• The peritoneal mesothelium is assumed to respond in the same way as the pleural 143 
mesothelium. 144 
 145 
5. Method comparison 146 
In general, inhalation testing is regarded as the most appropriate method for assessing the toxicity 147 
of airborne materials as it gives a realistic exposure scenario that can be extrapolated to humans 148 
(Pauluhn and Mohr, 2000). This view has been reflected in reviews conducted by various national 149 
and international agencies, including ILSI (2005) and the National Research Council (2000). Although 150 
inhalation testing can be expensive, time consuming and lack specificity in dose (Bernstein, 2007; 151 
Grimm et al., 2002) compared to intratracheal and intrapleural/intraperitoneal studies, there are a 152 
number of important problems associated with the alternative methods, as discussed for example 153 
by Lippmann et al. (2014). These include: bypassing of the natural defence mechanisms of the lung; 154 
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ability to inject/implant large fibres and particles that would not normally be inhaled into the deep 155 
lung; very high numbers/concentrations of test material at the injection site that may overwhelm 156 
defence mechanisms; targeted tissues (e.g. peritoneal mesothelium) are not the same as for 157 
inhalation exposure. Moreover, the coincidental injection of large (non-respirable) irritant fibres into 158 
the mesothelium may well confound the test results (Harrison et al, 2015). It is true to say that 159 
whilst inhalation studies may lead to exposure of the mesothelium, any toxic effect resulting from 160 
this would be expected to be picked up by histopathology. However, intraperitoneal studies cannot 161 
be considered to result in exposure of lung tissue. 162 
 163 
Some advantages and disadvantages of the various methods discussed above are summarised in 164 
Table 1. 165 
 166 
Table 1.  Some advantages and disadvantages of different exposure methods 167 
Exposure Method 
 
Advantages Disadvantages 
Inhalation • realistic exposure 
 
• expensive 
 
• actual applied dose more 
difficult to measure 
Intratracheal • lower cost 
• specified doses 
 
• long fibres can be delivered 
effectively to the lung   
• high bolus dose needed 
 
• uneven distribution; may 
block smaller bronchioles 
 
• overloading may occur 
 
• bypasses the upper 
respiratory tract 
 
• less reflective of chronic 
exposure for materials with 
low biopersistence 
Intraperitoneal/Intrapleural • lower cost 
• specified doses 
• sensitive  
 
• relevant to the determination 
of possible impacts on the 
mesothelium 
 
• bypasses the mechanical 
clearance system 
 
• may deposit larger diameter 
fibres than would normally 
reach the pleural cavity 
 
• not administered to the lung, 
thus effects on lung tissues 
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not investigated and fibres 
are not subject to natural 
attenuation within the lung 
Adapted from Miller et al., 1999; Wong, 2007 168 
With regard to dosimetry, uncertainties in inhalation studies can be reduced by lung burden 169 
experiments (using, for example, low temperature ashing and electron microscopy). Although in 170 
injection type methods the delivered dose can be measured, there remains uncertainty as to the 171 
true dose to the target organ. 172 
6. Comparison of toxicity study findings  173 
In the following sections, published toxicity data for a number of fibres and dusts obtained from 174 
inhalation (and, for some materials, intratracheal instillation) studies are compared with toxicity 175 
data for the same test materials delivered by the intraperitoneal and/or intrapleural routes. The 176 
chemical compositions of the fibres discussed in this report are detailed in Table 2 below (Bellmann 177 
et al., 1987; Bernstein, 2007; Grimm et al., 2002; Guldberg et al., 2002; Hesterberg et al., 1998; 178 
Kamstrup et al., 2001; Kamstrup et al., 2002; Kamstrup et al., 2004; Lambré et al., 1998; Roller et al., 179 
1996; Searl et al., 1999). While full characterisation of the delivered aerosol – especially 180 
fibre/particle size distribution – is extremely important, this information is not consistently available; 181 
this is acknowledged as a possible limitation when comparing test results.  182 
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Table 2.  Chemical composition of fibre types  183 
Chemical 
Composition 
(%)  
Crocidolite 
 
 
 
 
 
Chrysotile 
 
 
 
 
 
Amosite MMVF10 MMVF11 MMVF21 MMVF22 MMVF34 / 
HT 
Glass 
Fibres  
Type 
475 
RCF1 
RCF4 
RCF1a RCF2 
B₂O₃    8.75 4.5    10-12.1    
Na₂O 3.7 – 8.5  0.06 14.95 15.5 2.46-2.7 0.4 0.1-1.9 0.1-14.9 0.54 0.04 <0.3 
MgO 2.1 – 3.41 55.2 6.02 4.13 2.8 9.25-9.5 10 9.6-10.7 0.05-0.4 0.08 0.06 0.01 
Al₂O₃ 0.05 - 0.2  0.22 5.1 3.9 13-13.8 10.6 21.5-23.2 4.5-24 48 45.5 35 
SiO₂ 49 - 53 41.5 51.01 57.5 63.4 45.9-46.2 38.4 38.85-39.6 33-72.3 47.7 51.25 50 
K₂O 0.07 – 0.4  0.14 1.06 1.3 1.25-1.3 0.4 0.8 0.6-3 0.16 0.12 <0.01 
CaO 0.3-2.7 0.2 0.28 7.5 7.5 17 37.4 15 1.2-33 0.01 0.08 0.05 
TiO₂ 0.01   0.01 0.1 0.1-3 0.4 2-2.1 <0.1-3 2.05 1.84 0.04 
Fe₂O₃ 17-42.5 3 36.95 0.07 0.3 6.2-7 0.3 7.52 <0.1-6.4 0.97 0.89 <0.05 
ZnO -        2.8-4    
BaO -    <0.1 <0.1 <0.1 0.04 3.6-5    
P₂O₅ -     0.26  0.42     
MnO 0.05-0.12  3.44    2.15 0.3     
SO₃ 0.12    0.3 0.15-0.3 1.4 0.05     
F             
ZrO₂    0.03  0.03 0.06 0.06  0.11 0.04 15 
Other FeO 13 -20     0.4  0.9     
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6.1 Asbestos (Chrysotile, Crocidolite and Amosite)  184 
Muhle et al. (1987) carried out two parallel studies using inhalation and intraperitoneal models to 185 
assess the carcinogenic potential of chrysotile (UICC and Calidria) and crocidolite. In the 186 
intraperitoneal study, female Wistar rats (aged 5 weeks at the start of the trial) were administered a 187 
single intraperitoneal injection of 0.5 mg of crocidolite or chrysotile (Calidria) or chrysotile (UICC) in   188 
1 mL of saline, and observed for a median lifetime of 109 and 116 weeks for crocidolite and 189 
chrysotile respectively. In the inhalation study, female Wistar rats (aged 12 weeks at the start of the 190 
trial) were exposed via nose-only inhalation to 2.2 mg/m3 crocidolite and 6.0 mg/m3 chrysotile 191 
(UICC) for 5h, four times per week over a 12 month period (total exposure of 1000 h and cumulative 192 
exposure 2200 and 6600 mg/h/m3 respectively) with a 12 month follow-up exposure-free period. 193 
Exposure to crocidolite by intraperitoneal injection induced malignant tumours in 55% of animals 194 
compared with 84% in those exposed to chrysotile (UICC), and 0 – 6% in controls. Exposure to 195 
Calidria chrysotile was associated with malignant tumours in only 6% of animals, which the authors 196 
concluded was due to the lower biopersistence of Calidria chrysotile compared with UICC chrysotile. 197 
In contrast, no significant tumour incidence was reported for the inhalation studies, with only 2% (1 198 
animal) exposed to crocidolite developing an adenocarcinoma. Muhle et al. (1987) expressed doubts 199 
about the inhalation study findings.   200 
 201 
As part of a large study of 50 test materials, Pott et al. (1987) assessed the potential carcinogenicity 202 
of several types of chrysotile using an intraperitoneal model, and crocidolite using intratracheal and 203 
intraperitoneal models. Chrysotile (UICC A) given at doses of 6 and 25 mg to female Wistar rats via 204 
intraperitoneal injection, resulted in tumour incidences of 77.1 and 80.6% respectively. UICC B 205 
chrysotile administered at doses of 0.05, 0.25 and 1 mg by intraperitoneal injection was associated 206 
with a dose dependant increase in tumour incidence rate, with 19.4, 61.8 and 84.4% of rats 207 
respectively presenting with tumours. Two other forms of chrysotile, PVNO and calidria, were also 208 
tested, administered in a single intraperitoneal injection of 1 and 0.5 mg respectively. A high tumour 209 
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incidence rate of 80% was observed with the PVNO form, but a low incidence rate of only 6% was 210 
noted for the calidria form.  211 
 212 
Pott et al. (1987) also reported findings for crocidolite, tested in female Wistar rats using 213 
intratrachael and intraperitoneal models. Following intratracheal instillation of 20 doses of 0.5 mg, 214 
or a single intraperitoneal injection of 0.5 mg, similar numbers of tumours were evident, with 42.9% 215 
and 56.3% of animals, respectively, presenting with tumours. A higher tumour incidence rate was 216 
seen at the higher level of exposure of 2 mg crocidolite (87.5%) using the intraperitoneal model.  217 
 218 
Grimm et al. (2002) used crocidolite at 2 different doses (0.5mg and 5mg) as a positive control in a 219 
study of biosoluble insulation glass wool fibres, injected once into the intraperitoneal cavity of 220 
female Wistar rats (strain CrL: WiBR).  Pathology was carried out to determine presence of the 221 
following: mesothelioma with simultaneous abdominal tumours; other abdominal tumours with 222 
serosal spread (but no mesothelioma); and abdominal tumours with neither serosal spread nor 223 
mesothelioma. Survival numbers were significantly reduced in the high dose crocidolite group, 224 
leading to the validity of use of the high dose being questioned. Importantly, the authors concluded 225 
that there may be different aetiologies for the production of mesothelioma by soluble and insoluble 226 
fibres following intraperitoneal injection (Grimm et al., 2002).   227 
 228 
This study was an extension of an earlier investigation reported by Lambré et al. (1998) to evaluate 229 
the potential carcinogenic hazard of five man-made vitreous fibres, which also used crocidolite as a 230 
positive control.  Three different doses of crocidolite (0.005, 0.05 and 0.5mg), delivered in a single 231 
intraperitoneal dose to female Wistar rats, all produced mesotheliomas in a dose dependent manner 232 
(Lambré et al., 1998). In comparison to these intraperitoneal studies, Smith et al. (1987) used 233 
crocidolite as a positive control in a 2 year inhalation study in rats. A dose of 7 mg was associated 234 
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with fibrosis in half of the animals, with bronchioloalveolar hyperplasia also evident in a smaller 235 
number of animals. One mesothelioma and two bronchoalveolar tumours were reported.  236 
 237 
Hesterberg et al. (1995) also conducted long term inhalation studies using crocidolite and chrysotile 238 
as positive controls to validate the model used in their study. This used both rats (2 year exposure) 239 
and hamsters (18 month exposure), with the rats receiving crocidolite and chrysotile, and hamsters 240 
chrysotile, by nose only inhalation at a dose of 10mg m-3. The rats showed signs of pulmonary 241 
interstitial fibrosis with both fibre types after 3 months, and a single mesothelioma was present for 242 
each of the two asbestos fibres.  An increase in other lung tumours was also reported, but the exact 243 
tumour types were not detailed.  Due to the high mortality rate, the crocidolite exposure was 244 
stopped after 10 months.  The hamster group exposed to chrysotile also showed the presence of 245 
pulmonary fibrosis; however there was no evidence of mesothelioma or other lung tumours 246 
(Hesterberg et al., 1995).     247 
 248 
Both inhalation and intraperitoneal studies were conducted by Cullen et al. (2000a) using amosite 249 
asbestos in male Wistar rats (12 weeks of age). Inhalation exposure was carried out in a full body 250 
chamber, with exposure being equivalent to 1000 fibres/ml for 7 h per day, 5 days per week for up 251 
to 12 months, plus a further 12 month post-exposure recovery period. The intraperitoneal study 252 
comprised a single injection of 109 fibres in a 2ml suspension. In the inhalation exposure group, 4.8% 253 
of animals developed mesothelioma, while in the intraperitoneal group almost all (81%) developed 254 
mesothelioma. Carcinomas and adenomas of the lung were also present in the inhalation group, 255 
totalling 38.1% of animals.   256 
 257 
Intratracheal instillation of amosite (0.65mg/rat) was undertaken in a study by Padilla-Carlin et al. 258 
(2011). A single dose was instilled, producing a high degree of inflammation and pulmonary injury 259 
with thickening of the interstitial areas.  This was only a short-term study so no tumour observations 260 
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were made (details therefore not included in Table 3).  Comparing the results for intrapleural and 261 
inhalation exposure of amosite shows the material to be carcinogenic in both assays, but much more 262 
strongly so in the IP test. 263 
 264 
Summary of findings for asbestos 265 
• Chrysotile asbestos shows positive results for carcinogenicity in both inhalation (levels 266 
between 6 – 10 mg m-³) and intraperitoneal studies (levels between 0.05 – 25 mg), but with 267 
a much greater potency in the latter.  268 
• Crocidolite asbestos also shows positive results in both inhalation (levels between 2.2 – 10 269 
mg m-³) and intraperitoneal studies (levels between 0.005 – 5 mg), although there appears 270 
less difference in potency between the routes of exposure than with chrysotile asbestos. 271 
• Amosite asbestos shows positive results for carcinogenicity in both inhalation (1000 fibres/ 272 
cm-3) and intraperitoneal studies (109 fibres), although there is an apparent greater potency 273 
through the intraperitoneal route. 274 
 275 
6.2 Wollastonite 276 
Wollastonite was included in the large study of 50 test materials described by Pott et al. (1987). A 277 
total dose of 100mg was given by intraperitoneal injection, in five separate 20mg doses, to 54 rats. 278 
No tumours were observed 28 months after these injections, nor were any severe adhesions found. 279 
Inhalation and intratracheal studies have also been conducted on wollastonite by Warheit et al. 280 
(1994) and Tátrai et al. (2004) respectively. A short term inhalation study was carried out in male 281 
Sprague-Dawley rats, exposed to 115 mg/m3 (800 fibres/cc) for 5 days to assess biopersistence.  282 
Rapid clearance of the wollastonite fibres from the lungs was seen, with a low retention half-time of 283 
<1 week. The data indicated that wollastonite fibres have low durability, being composed of calcium 284 
silicates, resulting in solubilisation in the lung (Warheit et al., 1994). Tátrai et al. (2004) used a single 285 
1 mg intratracheal instillation of wollastonite, with crocidolite (UICC) as a positive control, and 286 
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examined the lungs at time intervals of 1, 3 and 6 months post exposure. The authors reported that 287 
the wollastonite exposed group showed mild inflammation and fibrosis which remained the same at 288 
six months as at one month, while the crocidolite showed increased inflammation at 6 months 289 
(Tátrai et al., 2004). All three exposure methods demonstrated that wollastonite has low toxicity. 290 
 291 
6.3 MMVFs (Man Made Vitreous Fibres) 292 
This section details findings on a variety of common MMVFs, including rock, slag and stone wool. 293 
Although strictly speaking RCF and special types of glass fibres are also classed as MMVFs, for clarity 294 
these are detailed in individual subsections. 295 
 296 
In 1972, intracavity experiments by Pott and Friedrichs (also Stanton and Wrench at the same time) 297 
indicated that man-made vitreous fibres could be a potential hazard to human health (Pott and 298 
Friedrichs, 1972; Stanton and Wrench, 1972); a large number of studies have subsequently been 299 
carried out on a variety of MMVFs using both inhalation and intraperitoneal exposure models.   300 
 301 
McConnell et al. (1994) conducted a long-term study in Fischer 344/N rats (males, eight weeks of 302 
age) exposed by nose-only inhalation for 6 h per day, 5 days per week, for 24 months to 3 303 
concentrations (3, 16, and 30 mg/m3) each of a rock wool (stone wool), and a slag wool (blast 304 
furnace). A dose-related non-specific inflammatory response was seen for both test substances, with 305 
rock wool also inducing a minimal local pulmonary fibrosis. Although a number of tumours were 306 
present (carcinoma and adenoma), their incidence was not considered to be significantly raised. 307 
Bronchoalveolar hyperplasia, on the other hand, was seen at significantly greater incidence in the 308 
highest dose animals than in the controls (saline) (McConnell et al., 1994).  Hesterberg et al. (1995) 309 
reported the toxicity of different MMVFs (including fibrous glass (MMVF10 and 11), rock (stone) 310 
wool (MMVF21) and slag wool (MMVF22)) by inhalation in a series of studies with comparable fibre 311 
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numbers (WHO fibres1) and dimensions in the delivered aerosols. Groups of rats and hamsters were 312 
exposed nose-only to 30mg m3 doses of each of the test substances for 6 h per day, 5 days per week 313 
for either 18 months (hamsters) or 24 months (rats). Exposure to the fibrous glasses and slag wool 314 
induced an inflammatory response in rats, but no mesotheliomas or increased lung tumour 315 
incidence rates were observed. Exposure to rock wool was associated with minimal lung fibrosis; 316 
there were no mesotheliomas and no increase in lung tumour rate. 317 
 318 
Miller et al. (1999) investigated the carcinogenicity and biopersistence of MMVF 10, 21 and 22 by 319 
intraperitoneal administration of 109 fibres.  MMVF21 showed results consistent with those of 320 
Kamstrup et al. (2001), with 95% of the test group developing mesothelioma. The MMVF10 and 321 
MMVF22 groups showed a lower incidence of mesothelioma (59% and 54% respectively); however, 322 
there was no control group included in this study, so it is not known if these results were statistically 323 
significant (Miller et al., 1999).  Comparing the results to those from the inhalation study reported by 324 
Hesterberg et al. (1995), it can be seen that there is no consistency between the findings, with 325 
mesotheliomas being produced by the intraperitoneal method but neither mesotheliomas nor lung 326 
tumours being found in the inhalation study.  327 
 328 
In a later study, Hesterberg et al. (1998), assessed the potential toxicity of a rapidly dissolving 329 
Synthetic Vitreous Fibre (X607) in Fischer rats, exposed by nose-only inhalation to X607 at a 330 
concentration of 200 fibres/cc for 6 h per day, 5 days per week for 24 months. RCF1 was included at 331 
the same exposure level and duration for comparison purposes (see Section 6.3.2). X607 showed low 332 
biopersistence and was not associated with fibrogenic or tumorigenic responses above those seen in 333 
the controls.  334 
 335 
                                                          
1
 WHO fibres are defined by the World Health Organization as having a length/diameter ratio ≥3, diameter <3 µm, and 
length >5 µm 
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Findings from the study reported by McConnell et al. (1994) were compared by Kamstrup et al. 336 
(2001) using an inhalation study to assess the pathology of a low silica/high aluminium content 337 
MMVF (34/HT). Male Fischer rats were exposed via nose-only inhalation to MMVF 34/HT at 338 
concentrations of 30 mg/m3 for 6 h per day, 5 days per week for 104 weeks, with a subsequent non-339 
exposure period lasting until survival of animals in the air control group had dropped to 340 
approximately 20%. Pathology results were compared to a previous assessment of stone wool 341 
(MMVF21) under the same exposure conditions reported by Hesterberg et al. (1995). The authors 342 
reported a marked difference in pulmonary pathogenicity, with MMVF21 but not MMVF34/HT2 343 
causing pulmonary fibrosis. Although tumours were present for both fibre types, these were 344 
comparable to control levels. 345 
 346 
No study utilising intraperitoneal/intrapleural models for MMVF34 could be identified for 347 
comparison to the data from the inhalation study.  However, Kamstrup et al. (2002) did conduct an 348 
intraperitoneal carcinogenicity study using the high aluminium, low silica HT wool RIF39001 and 349 
stone wool (D6) with similar chemical compositions to MMVF34 and MMVF21 respectively. This 350 
study administered a single dose of 9 mg of the HT wool, and 36 mg of D6, by intraperitoneal 351 
injection into female Wistar rats.  The mass dose differed for each fibre type due to differing number 352 
and size of the fibre. The HT wool dose (2.1 x 109 WHO fibres) was twice that since recommended by 353 
the EU guidelines (European Commission 1997). The animals administered the HT wool showed a 354 
low incidence (6%) of macroscopic nodules in the peritoneal cavity, while the majority of the group 355 
(88%) injected with D6 showed the presence of nodules. Histologically, clumps of fibres were found 356 
in the D6 groups either adherent to the surface of the viscera or free within the abdominal cavity, 357 
but not in the HT wool group. Formation of granulomas was seen in the D6 group, indicating a 358 
cellular response with but not in the HT wool group. Fibrosis was evident in the peritoneal cavity of 359 
both D6 (93%) and the HT group (58%), most commonly seen between the liver and diaphragm. 360 
                                                          
2
  Here and elsewhere, in fibre nomenclature HT denotes ‘high temperature’. 
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Three types of tumours (benign pituitary adenomas, mammary adenocarcinomas and 361 
mesothelioma) were observed in the treated animals and in the controls, but mesotheliomas were 362 
the most common type of tumour in the D6 group (56%). The authors concluded that the low 363 
carcinogenic potential of RIF39001 was due to the high biosolubility of the HT wool (Kamstrup et al., 364 
2002).   365 
 366 
Inhalation, intratracheal and intraperitoneal studies have been carried out to assess the carcinogenic 367 
potential of HT stone wool.  A single administration of 1.2 mg of stone wool in 0.2 ml by 368 
intratracheal instillation study was conducted by Baier et al. (2000) with sacrifices occurring at 369 
different time points up to 90 days post-exposure. Pulmonary granulomas were present at the start 370 
of the post instillation period but decreased as the post instillation time increased, with most of the 371 
granulomas being resolved and only a very small number of fibres remaining embedded in the 372 
surrounding tissue by the end of the study.  This study would appear to indicate that the HT fibre is 373 
unlikely to be carcinogenic, although this is not possible to determine categorically from a 90-day 374 
study (details therefore not included in Table 3).  No details on chemical composition of the fibres 375 
used were given by the authors, making comparison with other studies difficult. However, it is 376 
recognised that, due to differences in the processing of the raw materials and the variations that can 377 
occur in the starting material, it is not possible in practice to define a unique chemical composition 378 
for stone wools (Guldberg et al., 2002).   379 
 380 
Sub chronic and chronic inhalation studies have been carried out on high-aluminium, low-silica HT 381 
stone wools.  A sub-chronic biopersistence study tested 3 different stone wools (RIF41001, 42020-6 382 
and 43006-1) at a single dose of 150 fibres/ml (>20 µm) for a period of 3 months delivered by nose-383 
only exposure. A post exposure period of the same length was included. Only minimal 384 
histopathological changes were observed for all three stone wools, and therefore all were assessed 385 
as non-fibrogenic (Kamstrup et al., 2004). A chronic inhalation study was reported for MMVF34, 386 
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delivered to male Fischer 344 rats at 30 mg/m3 by nose-only inhalation for 6 h/day, 5 days/week for 387 
104 week, with a subsequent non-exposure period lasting until survival in the air control group had 388 
dropped to approximately 20%. No pulmonary fibrosis was noted with MMVF34 and the incidence of 389 
tumours was comparable with the control group (Kamstrup et al., 2001).  390 
 391 
Summary of findings for MMVFs 392 
Comparing the results of the inhalation and intraperitoneal tests for MMVF21/D6 and MMVF34 (or 393 
similar), the intraperitoneal test showed D6 to be carcinogenic, producing a tumour incidence rate of 394 
56%, while the inhalation tests showed both MMVF21 and MMVF34 to be non-tumorigenic. For HT 395 
stone wool, all three exposure models indicated no carcinogenic potential.  396 
 397 
Other studies of specific types of man-made vitreous fibres have been conducted and these are 398 
discussed separately below. 399 
 400 
6.4 Glass Fibres  401 
6.4.1 Glass fibre 104/475 402 
Pott et al. (1987) included a number of different types of glass fibres in their large study investigating 403 
the carcinogenicity of 50 fibres, dusts and metal compounds.  Glass fibre 104/475 was assessed 404 
using both intraperitoneal and intratracheal models.  In the intraperitoneal study, two separate 405 
doses of 104/475 (0.5 mg or 2.0 mg) were injected into the peritoneal cavity. A dose-dependent 406 
response for tumour induction was seen with incidences of 16.7 and 25.8% respectively.  In a further 407 
intraperitoneal study, five 1 mg doses were administered, with a post-exposure period of 28 months. 408 
Results of this study showed a high degree of fibrous adhesions and a 66% tumour rate. These two 409 
studies did not differentiate between tumour types, but combined incidences of sarcoma, 410 
mesothelioma or carcinoma in the abdominal cavity to give an overall tumour rate. In the 411 
intratracheal study, a 10 mg dose of 104/475 was instilled in 20 weekly injections of 0.5mg each, 412 
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resulting in a 14.7% incidence of lung tumours (types not differentiated).  Pott et al. reported that 413 
this was statistically significant when compared to the unexposed control group of animals in which 414 
no tumours were evident (Pott et al., 1987).  A further study by Muhle et al. (1987) compared 415 
findings from intraperitoneal and inhalation studies using 104/475. Female Wistar rats were 416 
administered a single intraperitoneal injection of 0.5mg 104/475, while in the inhalation group 417 
female Wistar rats were exposed, nose-only, to 104/475 at a concentration of 3.0 ± 1.8 mg/m3 for 5 418 
hours per day, 4 days a week for 1 year with a total study duration of 2 years.  Following 419 
intraperitoneal injection, a total tumour incidence rate of 17% was observed (tumour types not 420 
specified). This compared with only one primary lung tumour (squamous cell carcinoma) following 421 
inhalation exposure, although there was a high incidence of fibrosis (38%), with bronchioloalveolar 422 
hyperplasia (11%) and squamous metaplasia (0.9%) in these animals.  423 
 424 
6.4.2 Glass fibre 100/475 425 
Glass fibre 100/475 differs from 104/475 in that it has a smaller diameter.  Davis et al. (1995) 426 
reported findings of a review comparing models to predict the pathogenicity of fibres, utilising 427 
100/475 as an example of a less durable glass microfibre (details not included in Table 3).  Cullen et 428 
al. (2000a) have reported findings of both inhalation and intraperitoneal studies using 100/475. Rats 429 
were exposed to aerosol concentrations of 1000 fibres/ml for 7 h per day, 5 days per week for 12 430 
months, with an additional post-exposure period of 12 months. After 2 years, no fibrosis was 431 
apparent, nor were there any carcinomas or mesotheliomas; however adenomas were detected in 432 
10.5% (4/38) of animals.  For the intraperitoneal study, a single administration of 109 WHO fibres 433 
was used, with mesothelioma being detected in 33% of rats (8/24) (Cullen et al., 2000a).  434 
 435 
These results indicate that in a similar way to glass fibre 104/475, glass fibre 100/475 shows little or 436 
no carcinogenic potency by inhalation but induces a strong (33%) mesothelioma response following 437 
intraperitoneal injection. 438 
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 439 
6.4.3 E Glass 440 
In the Cullen et al. study carried out to assess the carcinogenic potential of glass fibre 100/475 441 
discussed above, 104E glass fibres (“E Glass”) were also assessed at an inhalation exposure level of 442 
1000 fibres/ml for 7 h/day, 5 days/wk over 12 months. Glass fibre 104E was shown to include a large 443 
amount of very fine fibres (<0.1um diameter). At the end of the exposure period, 4 of 47 rats in the 444 
exposure group were sacrificed; lung histopathology showed alveolar thickening, macrophage 445 
infiltration and pulmonary fibrosis.  Following the 12 month recovery period, histopathology showed 446 
advanced alveolar fibrosis and bronchoalveolar hyperplasia, with 7 carcinomas, 3 benign adenomas 447 
and 2 mesotheliomas in the remaining animals. Cullen et al., (2000a) also assessed 104E glass fibres 448 
using an intraperitoneal model, with a single injection of 1000 fibres. In this study, the majority of 449 
the group (87.5%; 21/24) developed mesothelioma. Thus both the IP and inhalation methods 450 
showed 104E to be carcinogenic. 451 
 452 
6 .4. Refractory Ceramic Fibres (RCF)
3
  453 
The carcinogenicity of Fiberfrax ceramic wool has been assessed using inhalation, intraperitoneal 454 
and intratracheal models. An inhalation study in rats did not result in tumours, but was associated 455 
with fibrosis in 22% of animals. In the hamster, a mesothelioma incidence of 1% was recorded with a 456 
low incidence of fibrosis (1%) (Smith eta l., 1987). Intratracheal studies showed no, or very small 457 
tumour incidence rates numbers, whereas intraperitoneal studies reported high incidences of 458 
tumours (68.1 and 83%) in two separate studies (Smith et al., 1987; Pott et al., 1987). 459 
 460 
In a one year inhalation study, Mast et al. (1995a) assessed the toxicity/carcinogenicity of three 461 
types of size-selected (length 20 µm and diameter 1 µm) RCF fibres - kaolin-based, high purity, and 462 
aluminium zirconia silica - delivered at 30 mg (220 fibres/cm-3). Interstitial and pleural fibrosis was 463 
                                                          
3
 More correctly called aluminium silicate wools (ASW). Composition of these fibres varies according to the 
specific ingredients and quantities used in their manufacture. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
23
apparent from 6 and 9 months respectively for all fibres. Pulmonary neoplasms (bronchoalveolar 464 
adenomas and carcinomas) were observed in 13, 15.7 and 7.4% of animals exposed to kaolin-based, 465 
high purity and aluminium zirconia silica fibres respectively; these were statistically significantly 466 
higher than unexposed controls. Pleural mesotheliomas were observed in 1.6% of animals exposed 467 
to kaolin-based RCF, in 2.5% exposed to high-purity RCF and 1.7% exposed to aluminium zirconia 468 
silica RCF.  469 
 470 
A two-year multi-dose inhalation study by the same authors using kaolin-based RCF (as described 471 
above) at levels of 3, 9 or 16 mg m-3 (36, 91 and 162 fibres/cm-3 respectively) reported interstitial 472 
fibrosis and focal pleural fibrosis at 12 months in the two highest dose groups. Neoplasms 473 
(bronchoalveolar adenomas and carcinomas) were observed in 1.6, 3.9 and 1.6% of animals exposed 474 
to kaolin-based RCF at 3, 9 and 16 mg m-3 respectively; these incidences were not statistically 475 
significantly higher than in the unexposed controls. A single pleural mesothelioma was also observed 476 
in one animal (0.8%) exposed to 9 mg/m3 of kaolin-based RCF (Mast et al., 1995b).  477 
 478 
In a subsequent review of their single-dose RCF study (Mast et al., 1995a) using mathematical 479 
modelling to assess deposition, clearance and retention of RCF fibres and taking into account the 480 
concept of ‘overload’, Mast et al. (2000) suggested that a level of 30 mg m-3 may have exceeded the 481 
maximum tolerated dose, which would have overloaded the lung and had a major impact on the 482 
observed chronic adverse effects (Mast et al., 2000). 483 
 484 
The RCF sample used in the Mast et al. studies is believed to contain more non-fibrous materials 485 
than MMVFs, which could have had a serious effect on the results obtained, potentially leading to a 486 
false positive result. Therefore, in a subsequent study the RCF1 (kaolin-based) sample administered 487 
was processed in the same way as MMVF samples, as reported by Hesterberg et al. (1995), giving 488 
RCF1a.  489 
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 490 
The size-selected RCF1a sample was used by Bellmann et al. (2001) in a short term nose-only 491 
inhalation study and compared to the results for the original RCF1.  Female Wistar rats were 492 
exposed for 6 h/day, 5 days/wk for 3 wk to either RCF1a or RCF1 fibre aerosol at a concentration of 493 
about 125 fibres (>20µm long)/ml; due to differences in the nonfibrous particle content, the average 494 
gravimetric aerosol concentration differed between the two samples (RCF1, 51.2 mg/m3; RCF1a, 495 
25.8 mg/m3). The post-treatment observation period was 12 months. The clearance function of 496 
alveolar macrophages was seen to be severely retarded following exposure to RCF1 but not RCF1a. 497 
In both groups, a significant increase in polymorphonuclear leukocyte and lymphocyte counts was 498 
shown 3 days following the end of exposure, which persisted longer (remaining high at 3 months 499 
post exposure) in the RCF1 group than in the RCF1a, indicating persistent inflammation. 500 
Histopathology showed the presence of inflammatory changes, with similar fibrotic and hyperplastic 501 
changes in both RCF1a and RCF1; however, at the end of the 12 month post exposure period the 502 
fibrotic changes were only present in the RCF1 group.  The authors suggested that the difference in 503 
the results between RCF1 and RCF1a could be explained by an increased number of shorter fibres 504 
(falling outside the WHO definition) in RCF1a compared to RCF1, and also noted that the numerous 505 
lesions seen in the RCF1 exposure group resembled those seen in a lung overload study. This study 506 
casts thus further doubts on the RCC studies on RCF, and also raises the issue that non-fibrous 507 
components found in the administered aerosol could lead to inflammation and in turn tumour 508 
production (Brown et al, 2000; Bellmann et al., 2001).   509 
 510 
An intraperitoneal study was conducted as part of the Colt Fibre Research Programme (CFRP) using 511 
RCF1, at a target dose of 109 WHO fibres (Miller et al., 1999) This study not only looked at 512 
mesothelioma production, but also the importance of fibre length, biopersistence and dissolution 513 
rate in relation to tumour production.  Administration of RCF 1 was associated with an 88% 514 
incidence of mesotheliomas. The intraperitoneal exposure method using RCF1 thus produced a high 515 
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incidence of tumours, differing significantly from the inhalation method. Miller et al. (1999) also 516 
reported mesothelioma in rats administered zirconia aluminosilicate RCF2 (188.8 mg) by 517 
intraperitoneal injection, with an incidence of 72%. 518 
 519 
6.5 Titanium Dioxide 520 
Titanium dioxide (anatase) was used as a non-carcinogenic control dust in the large carcinogenicity 521 
study of around 50 dusts conducted by Pott et al. (1987). Doses ranging from 10 to 100 mg were 522 
administered by the intraperitoneal route, resulting in tumour rates of between 0% and 9.4% (see 523 
Table 3). Muhle et al. (1987) similarly reported an absence of tumours following administration of a 524 
single intraperitoneal dose of 10 mg of the anatase form of titanium dioxide. Pott and Roller 525 
included the anatase form of titanium dioxide (ultra-fine and fine) in their large study of 19 dusts. 526 
Intratracheal instillation of ten 6 mg doses resulted in 69.6% and 29.5% incidence of tumours for the 527 
ultra-fine and fine forms respectively (Pott and Roller, 2005). It is likely that these high tumour yields 528 
were due to an overload effect consequent to the very high doses delivered (total 60mg).  529 
 530 
The rutile form of titanium dioxide was used by Cullen et al. (2000b) in an inhalation study at two 531 
doses (25mg/m3 for 209 days and 50 mg/m3 for 118 days) designed to produce overload effects.  A 532 
whole body exposure chamber was used, with animals being exposed for 7 hours per day for 5 days 533 
a week and sacrificed at 6 different time points.  Histopathological examination showed Type II 534 
hyperplasia with thickening of the alveolar walls, and the presence of macrophages containing dust 535 
particles, but no significant fibrogenic activity (Cullen et al., 2000b).  These findings are in agreement 536 
with those reported by Donaldson et al. (1988) from an inhalation study on titanium dioxide 537 
delivered to rats at 10mg/m3 over periods of 32 and 75 days (Donaldson et al., 1988).  However, Lee 538 
et al. (1986) reported contrasting findings from a 2 year inhalation study involving exposure to 10, 50 539 
and 250 mg/m3 rutile titanium dioxide. At the lowest dose, dust laden macrophages were noted; at 540 
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the medium dose, thickening of the alveolar walls in addition to macrophage infiltration and one 541 
bronchoalveolar adenoma was found.  The highest dose animals showed similar responses to those 542 
of the mid dose group in the first year, but went on to develop bronchoalveolar adenomas and 14 543 
cystic keratinizing squamous carcinomas in 25 (from a total of 151) animals, although these were 544 
difficult to differentiate from squamous metaplasia.  While tumours were seen to develop in this 545 
study, it was determined that this was due to the excessive dose used (leading to overload 546 
conditions) in the study which is unlikely to occur or be relevant to human exposure (Lee et al., 547 
1986).   548 
 549 
For titanium dioxide, the inhalation, intratracheal and intraperitoneal models all generally indicate 550 
no or low carcinogenic potential except when exceptionally high doses are administered, leading to 551 
overload effects.  552 
 553 
6.6 Silicon Carbide  554 
6.6.1 Silicon carbide whiskers 555 
Intraperitoneal, inhalation and intrapleural studies have been conducted on silicon carbide whiskers. 556 
In a dose-range finding study, Adachi and colleagues administered a single dose of 10 mg/rat of nine 557 
different fibre types including silicon carbide whiskers by the intraperitoneal route to female F344 558 
rats. This resulted in development of peritoneal mesothelioma in all test animals within a year, 559 
leading the authors to conclude that a reduced dose of 5 mg/rat of silicon carbide whiskers was 560 
appropriate for the main study. A year after administration of 5mg/rat, 70% of the animals had 561 
developed mesothelioma (Adachi et al., 2001).  UICC chrysotile B was used as a positive control, 562 
resulting in a 70% incidence of mesothelioma, one year after administration. 563 
 564 
In a long-term study, rats were exposed by whole-body inhalation to silicon carbide whiskers for 7 565 
hours/day, 5 days/week, for 41 weeks; amosite asbestos was used as a positive control (Davis et al., 566 
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1996). Following the exposure period some rats (n=42) were assessed for life and in these animals 20 567 
tumours of the lung and pleura were recorded (5 carcinomas, 5 adenomas and 10 malignant 568 
mesotheliomas). A few animals had more than one type of tumour so that the number of tumour-569 
bearing animals was reported to be 16. In comparison to amosite, silicon carbide produced fewer 570 
tumours in the lung parenchyma, but produced a total of 10 mesotheliomas compared with 2 571 
related to amosite exposure. 572 
 573 
In a biopersistence inhalation study, male Wistar rats were exposed to silicon carbide whiskers at a 574 
concentration of 2.6 ± 0.4 mg/m3 (98 ± 19 fibres/ml) for 6 hours a day, 5 days a week for up to 1 year 575 
(Akiyama et al. 2007). This dose was chosen as it was close to the occupational exposure limit for 576 
silicon carbide whiskers at that time.  Histopathological examination showed fibrotic changes in the 577 
lung including thickening of the alveolar walls, macrophage infiltration, aggregation of fibres, and 578 
bronchoalveolar hyperplasia in two animals.  579 
 580 
Johnson and Hahn (1996) reported findings of a carcinogenicity study using a single intrapleural 581 
administration of 20 mg silicon carbide whiskers of different lengths, containing either 5.6×108 582 
fibres/kg bw, 1.2×107fibres/kg bw or 8×108 fibres/kg bw (named SiCW 1, SiCW 2 and SiCW 3 583 
respectively) to female rats. Animals were assessed over their lifetime and those treated with SiCW 584 
1 and SiCW 2 developed pleural mesotheliomas at a rate of 90% and 87% respectively. In 585 
comparison, 23% of those treated with SiCW3 and 57% of the positive controls treated with 586 
crocidolite developed pleural mesotheliomas.   587 
 588 
6.6.2 Granular silicon carbide 589 
The granular, non-fibrous, form of silicon carbide has been assessed through intraperitoneal studies. 590 
Roller et al. (1996) examined groups of male or female rats for up to 30 months for tumours in the 591 
abdominal cavity after repeated (5 or 20) intraperitoneal injections of 50 mg of granular silicon 592 
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carbide (equivalent to approximately 667 mg/kg bw and 2,666 mg/kg bw). From a total of 395 rats, 593 
only two mesotheliomas were found. Pott et al. (1994) also reported no increase in tumours in a 594 
carcinogenicity study with non-fibrous silicon carbide administered to rats by repeated (5 or 20) 595 
intraperitoneal injections of 50mg (equivalent to approximately 667 mg/kg bw and 2,666 mg/kg bw). 596 
 597 
6.7 Potassium Octatitanate 598 
The intraperitoneal study carried out by Adachi et al. (2001) described above, also investigated 599 
potassium octatitanate under the same conditions of exposure. In the dose-range finding study, a 600 
77% incidence of mesothelioma was present, indicating that a reduced dose of 5mg/m3 was 601 
appropriate for the follow-on study. In the second study, exposure to potassium octatitanate 602 
resulted in an incidence of 20% mesotheliomas (Adachi et al., 2001).  603 
 604 
Yamato et al. (2003) conducted a low exposure (2.2 ± 0.7 mg/m3 or 111 ± 34 fibres/ml) long term 605 
inhalation study, exposing male Wistar rats to potassium octatitanate for one year for 6 h per day, 5 606 
days per week. Histopathology showed the presence of mild fibrotic changes around macrophages 607 
that had engulfed the fibres at 3 days, 6 and 12 months. No malignant pulmonary tumours were 608 
observed, although adenomas were found in 2 rats (3.4%; 2/59) at 6 months post exposure and in 1 609 
rat (1.7%; 1/59) at 12 months. Squamous metaplasia was also found in 1 rat (1.7%; 1/59) at the 12 610 
month period.  In a chronic inhalation study, Ikegami et al., (2004) reported toxicological findings 611 
following exposure of male Fischer 344 rats via whole-body inhalation to 0, 20, 60, or 200 WHO 612 
fibres/cc of potassium octatitanate for 6 h/day, 5 days/w for 24 months. At the mid dose, alveolar 613 
wall thickening and minimal alveolar fibrosis were noted following 18 and 24 months of exposure. At 614 
200 fibres/cc exposure, slight alveolar wall thickening was apparent after 12 months of exposure and 615 
slight alveolar fibrosis after 18 and 24 months of exposure. No exposure-related pulmonary 616 
neoplasms or mesotheliomas were observed.  617 
 618 
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An intratracheal instillation study investigating lung burden and biopersistence was carried out by 619 
Oyabu et al. (2006) utilising data from the inhalation study reported by Yamato et al. (2003).  The 620 
authors interpreted that the data showed a threshold and that the dose would lie between 1.5 and 621 
2.4 mg; one of four doses (0.5, 1, 2 and 5mg) were therefore instilled into male Kud:Wistar rats, 622 
which were sacrificed at different time points for up to one year. Dose-related fibrotic changes and 623 
thickening of the alveolar wall were observed (not included in Table 3 as no quantitative data). Thus 624 
inhalation and intratracheal exposure to potassium octatitanate gave rise to no malignant tumours, 625 
whilst the intraperitoneal study produced a high tumour yield. 626 
 627 
6.8 Quartz 628 
Quartz (a known macrophage toxin) was one of the dusts included in two of the intraperitoneal 629 
studies carried out in the large study by Pott et al. (1987).  The two doses used (10 mg and 40 mg) 630 
induced tumours (sarcoma, mesothelioma or carcinoma in the abdominal cavity) at rates of 5.9% 631 
and 22% respectively. These results can be compared to those from intratracheal instillation 632 
experiments carried out using quartz. In a short-term (1 month) study, Luchtel et al. (1989) used 633 
quartz as a positive control at a single dose of 5mg, which was associated with fibrotic lesions and 634 
increased numbers of macrophages in the alveoli (study not included in Table 3 due to short 635 
duration). In 2005, Pott and Roller conducted the “19 dust study” to test the carcinogenicity of a 636 
number of dusts using intratracheal instillation.  Quartz was used as a positive control due to its 637 
known toxicity. Exposure to single instillation doses of 5 and 10 mg resulted in total tumour 638 
(adenoma, adenocarcinoma or squamous mixed cell carcinoma in the lung) incidences of 65.7% and 639 
71.4% respectively. Instillation of a higher dose of 20 mg, delivered in two doses of 10 mg each, 640 
resulted in a 77.8% incidence of total lung tumours (Pott and Roller, 2005).   641 
 642 
Although intraperitoneal and intratracheal studies confirm a tumorigenic response in the lungs 643 
following exposure to quartz, a difference in the degree of tumour development is evident.  At the 644 
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10 mg dose level, intraperitoneal injection resulted in an incidence of 5.9% tumours (Pott et al., 645 
1987) while the intratracheal study gave rise to 57.1% tumours (Pott and Roller, 2005).  646 
 647 
6.9 Kevlar 648 
The aramid fibre ‘Kevlar’ was assessed for carcinogenic potential by Pott et al. (1987) using an 649 
intraperitoneal model, and by Warheit et al. (1994) in a 3 month inhalation study. In the 650 
intraperitoneal study, 5.8% of rats administered 20 mg of Kevlar fibres (5 x 4mg) showed tumour 651 
development.  In the inhalation study, Crl:CD BR rats were exposed for 5 days to aerosols of Kevlar 652 
fibrils (900-1344 f/cc; 9-11 mg/m3). No pulmonary lesions were observed, which was considered to 653 
be due to the rapid clearance of the Kevlar fibres. One chronic inhalation study on Kevlar has been 654 
reported by Lee et al. (1988). Rats (male and female) were exposed to Kevlar fibrils at concentrations 655 
of 0, 2.5, 25, and 100 fibrils/cc for 6 h per day, 5 days per week for 2 years. One group was also 656 
exposed to 400 fibrils/cc for 1 year and allowed to recover for 1 year. Lung tumours were observed 657 
in treated animals, however, the authors considered these to be a unique type of experimentally 658 
induced tumour (cystic keratinizing squamous cell carcinoma) and not of relevance to the human 659 
situation.   660 
 661 
Thus both intraperitoneal and inhalation experiments appear to indicate low carcinogenic potential 662 
for Kevlar.   663 
 664 
6.10 Polypropylene 665 
Polypropylene fibres have been assessed for carcinogenic potential using inhalation and 666 
intraperitoneal exposure models.  Hesterberg et al. (1992) administered polypropylene fibres at 15, 667 
30, or 60mg/m3  (actual doses achieved were 13.03, 28.07 and 59.61 mg/m3) by nose-only inhalation 668 
to male Fischer rats for 6 h per day, 5 days per week for 90 days. A dose-dependent increase in 669 
pulmonary macrophages and reversible increase in mild cellularity were noted. In an intraperitoneal 670 
study carried out by Pott et al. (1987) as part of a large carcinogenic study of around 50 dusts, 671 
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female Wistar rats were administered 50mg of polypropylene fibres (5 doses of 10 mg), resulting in 672 
only a 2% tumour incidence.   673 
 674 
Thus both exposure methods provide evidence that polypropylene fibres are non-carcinogenic (Pott 675 
et al., 1987; Hesterberg et al., 1992).  676 
 677 
Table 3 shows a comparison of all available results for each of the fibre types used in the inhalation, 678 
intratracheal and intraperitoneal studies described above. The data have been collated to include 679 
the dose and size (distribution given where available in original study) of each fibre type, along with 680 
(where available) the types of tumour produced, whether fibrosis was present, and the total 681 
percentage of tumours produced. It should be noted that for accuracy, exposure concentration is 682 
given as cited in the original study (i.e. fibre number is given only when originally cited), however, 683 
should the reader wish to do so, calculations are available to convert gravimetric concentration to 684 
fibre number/cm3. In addition, cumulative exposure is cited if given in the original study, if not cited, 685 
exposure durations are detailed should the reader wish to calculate the cumulative dose.  686 
  687 
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Table 3 Summary of toxicity study findings utilising inhalation, intratrachael and intraperitoneal models of exposure 688 
Reference Material 
 
Exposure 
Method 
IH/IT/IP 
Exposure 
Duration 
(hrs/day, 
days/wk, 
total 
months, 
INH) or 
months 
(IP)
1
 
Length 
(µm) 
 
Diamet-
er (µm) 
 
Mass / Fibre 
concent-
ration
2
,
3
 
 
 
Percentage of animals with tumours / histopathological lesions
4
 
Mesothelium/abdominal 
cavity 
Lung 
Mesothelioma Total 
abdominal 
tumours 
Carcinoma Adenoma Bronchiolo-
alveolar 
hyperplasia 
Fibrosis Total 
pulmonary 
tumours 
Asbestos 
Hesterberg 
et al.. 1995 Chrysotile 
 
IH (rat) 
 
 
6.5.24 
>5 <3 
10mg m
-
³ 
(1.1 ± 1.1 
x10
4
 WHO 
fibres/cm
-3
) 
 
1.4 NS NS NS NS Yes  18.9 
Chrysotile 
 
IH (hamster) 
 
 
6.5.18 
10mg m
-
³ 
(3000 ± 
1400 WHO 
fibres/cm
-3
) 
 
0 0 0 0 0 No 0 
Muhle et 
al., 1987 
Chrysotile 
(UICC) 
 
IH 
 
 
5.4.12 
(12 month 
follow-up)  2.0 - 14 
0.28 - 
1.6 
6.0 mg m
-
³ 
(131 + 72 
fibres 1 > 5 
µm) 
SD 
 
Cumulative 
exposure of 
6000 mg h 
m
-3
 
- - 0 0 12 
Yes  
(42) 
12 
Chrysotile 
(UICC) 
 
IP 
 
24 
0.3 - 3.6 
0.08 - 
0.18 
1.0 mg 
SD
 
(single dose) 
NS 84 - - - - - 
Chrysotile 
(Calidria) 
 
24 
0.4 - 5.9 
0.02 - 
0.10 
0.5mg 
SD 
(single dose) 
NS 6 - - - - - 
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IP 
Pott et al., 
1987 
 
 
Chrysotile 
(UICC A) 
 
IP 
Up to 30 
9 0.15 
6 mg (single 
dose) 
NS 77.1 - - - - - 
Up to 30 25 mg 
(single dose) 
NS 80.6 - - - - - 
Chrysotile 
(UICC B) 
 
IP 
Up to 30 
0.9 0.11 
0.05 mg 
(single dose) 
NS 19.4 - - - - - 
Up to 30 0.25 mg 
(single dose) 
NS 61.8 - - - - - 
Up to 30 1 mg (single 
dose) 
NS 84.4 - - - - - 
Chrysotile 
(PVNO) 
 
IP 
Up to 30 
0.9 0.11 
1 mg (single 
dose) 
NS 80.0 - - - - - 
Chrysotile 
(Calidria) 
 
IP 
Up to 30 
1.2 0.03 
0.5 mg 
(single dose) 
NS 6.3 - - - - - 
Adachi et 
al., 2001 
 
Chrysotile  
(UICC B) 
 
IP 
 
24 
 
>5 
 
<3 
 
10 mg (10 x 
1 mg) 
85 85 - - - - - 
Smith et al., 
1987 
Crocidolite 
(UICC) 
IH  
 
6.5.24 
 
≤5 
(95%) 
 
2.5 ± 
0.2 µm- 
7 mg 
3000 
fibres/cm
-3 
SD
 
1.8 NS NS NS 8 
Yes  
(53) 
3.5 
Muhle et 
al., 1987 
Crocidolite 
(South Africa) 
IH 
5.4.12 
(12 month 
follow-up) 
 
0.72 – 
4.5 
 
0.17 – 
0.46 
2.2 (± 1.3) 
mg m
-3 SD 
 
Cumulative 
exposure of 
2200 mg h 
m
-3
 
- - 1 0 74 
Yes 
 (36) 
76 
Crocidolite 
(South Africa) 
 
IP 
24 0.5 mg 
SD 
(single dose) 
NS 55 - - - - - 
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Hesterberg 
et al., 1995 
Crocidolite 
 
IH 
 
6.5.24 
>5 <3 
10 mg m
-3
 
(0.16 ± 0.1 
x10
4
 WHO 
fibres/cm
-3
) 
0.9 0.9 NS NS NS Yes 14.2 
Pott et al., 
1987 
Crocidolite 
 
IT 
Up to 30  
2.1 
 
0.2 
10 mg           
(20 x 0.5) 
- - 31.4 0 - - 42.9 
Crocidolite 
 
IP 
Up to 30  
0.5 mg 
NS 56.3 - - - - - 
 2 mg 
-  - - - - - 
Lambre et 
al., 1998 
 
 
Crocidolite 
 
IP 
 
32.5 
>5 <2 
0.005 mg 
(1.9 x 10
6
  
fibres) 
SD 
(single dose) 
7.8 7.8 - - - - - 
 
32.5 
0.05 mg 
(18.9 x 10
6
  
fibres)
 SD
 
(single dose) 
15.7 19.6 - - - - - 
 
32.5 
0.5 mg 
(188.6 x 10
6
  
fibres)
 SD
 
(single dose) 
39.2 49.0 - - - - - 
Grimm et 
al., 2002 
Crocidolite 
 
IP 
31 
>5,  <15 <3 
27 mg  
(0.5 x 10
6
 
WHO fibres)
 
SD
 (single 
dose) 
52.9 NS - - - - - 
31 45 mg   
(5.0 x 10
6 
WHO fibres) 
SD  
(single 
dose) 
88.2 NS - - - - - 
Cullen et al., 
2000a 
Amosite 
 
IH 
 
 
7.5.12 (12 
month 
follow-up) 
>0.4, 
<20 
>0.1, 
<0.9 
1000 fibres/ 
cm
-3
 
4.8 NS 16.7 21.4 - Yes 38.1 
Amosite 
 
24 10
9
 fibres 
(single dose) 
81 NS - - - Yes NS 
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IP 
Wollastonite 
Warheit et 
al. 1994 
Wollastonite 
 
IH 
6.5.0 
 (6 month 
follow-up) 
- 
Aero-
diam 
2.6 (± 
2.0) – 
4.3 (± 
2.2) µm 
- 
59 - 114 mg 
m
-3
  (123 - 
835 fibres/ 
cm
-3
) 
- - - - - 
Yes 
(mild) 
- 
Tátrai et al. 
2004 
Wollastonite 
 
IT 
6 10 – 20 
(median
) 
≤ 1 
(media
n) 
1 mg (single 
dose) 
SD
 
- - - - - 
Yes 
(mild) 
- 
Pott et al. 
1987 
Wollastonite 
 
IP 
Up to 30 
5.2 1.1 
100 
(5x20mg ) 
NS 0 - - - - - 
Man-made vitreous fibres 
McConnell 
et al. 1994 
MMVF rock 
wool 
 
IH 
6.5.24 
>5 <3 
3, 16, 30        
mg m
-3
 
No - - - - 
Yes          
(v  mild 
for all 
doses) 
NS 
MMVF slag 
wool 
 
IH 
 
 
6.5.24 
>5 <3 
3, 16, 30        
mg m
-3
 
No - - - - 
No (for 
all 
doses) 
NS 
Hesterberg 
et al. 1995 
MMVF 
10 (fibreglass) 
 
IH 
6.5.24 
0 - > 100 0 - > 3 30 mg m
-3 SD
 
0 0 NS NS NS No 5.9 
MMVF 11 
(fibreglass) 
 
IH 
6.5.24 
0 0 NS NS NS No 2.7 
MMVF 21 
(rock wool) 
 
6.5.24 
0 0 NS NS NS Yes 4.4 
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IH 
MMVF 22 
(slag wool) 
 
IH 
6.5.24 
0 0 NS NS NS No 2.6 
Hesterberg 
et al. 1998b 
Synthetic 
vitreous fibre 
X607 
 
IH 
6.5.24 
11 ± 4 
0.9 ± 
0.3 
30 (± 6) mg 
m
-3
 
 
(174 ± 72 
WHO 
fibers/cm
-3
) 
SD
 
0 - 0.8 0.8 4.9 - 1.6 
Kamstrup et 
al. 2001 
Stone wool – 
HT 
(MMVF34) 
 
IH 
 
 
6.5.24 11.1 0.98 30 mg m
-3
 - 7 4.7 5.6 - No NS 
Kamstrup et 
al. 2004 
Stone wool – 
HT 
RIF41001 
 
IH 
6.5.3 
(3 month 
follow-up) 
44.2 ± 
1.7 
0.75 ± 
1.9 
15, 50, 150 
fibres/ cm
-3
          
(>20 µm 
long) 
- - - - - 
No for 
all doses 
(after 3 
months) 
NS 
RIF42020-6 
 
IH 
6.5.3 
(3 month 
follow-up) 
36.5 ± 
1.5 
0.72 ± 
1.9 
15, 50, 150 
fibres/ cm
-3
          
(>20 µm 
long) 
- - - - - 
No for 
all doses 
(after 3 
months) 
NS 
RIF43006-1 
 
IH 
6.5.3 
(3 month 
follow-up) 
38.1 ± 
1.6 
0.63 ± 
1.2 
15, 50, 150 
fibres/ cm
-3
           
(>20 µm 
long) 
 
- - - - - 
No for 
all doses 
(after 3 
months) 
NS 
Miller et al. 
1999 
 
MMVF10 
(glass wool) 
 
IP 
Assessed 
for life 
>0.4 - > 
20 
 
< 0.95 
> 0.95 
144.4 mg 
(single dose)
 
SD
 
59 - - - - - - 
MMVF21 
(stone wool) 
 
IP 
Assessed 
for life 183.1 mg (as 
2 doses)
 SD
 
95 - - - - - - 
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MMVF 22 
(slag wool) 
 
IP 
Assessed 
for life 
129.6 mg 
(single dose)
 
SD
 
54 - - - - - - 
Glass Fibres 104/475 
Muhle et al. 
1987 
Glass fibre 
104/475 
 
IH 
5.4.12 
(12 month 
follow-up) 2.0 – 
12.4 
0.23 – 
0.80 
3.0 mg m
-3 SD 
 
Cumulative 
exposure of 
3000 mg h 
m
-3
 
- - 0.9 0 11 
Yes  
(38) 
NS 
Glass fibre 
104/475 
 
IP 
24 
1.4 – 8.4 
0.09 – 
0.40 
0.5 mg 
SD
 
(single dose) 
NS 17 - - - - - 
Pott et al. 
1987 
Glass fibre 
104/475 
 
IT 
Up to 30 
3.2 0.18 
10 mg            
(20 x 0.5 mg) 
- - 11.8 2.9 - - 14.7 
Glass fibre 
104/475 
 
IP 
Up to 30 0.5 mg 
(single dose) 
NS 16.7 - - - - - 
Up to 30 2 mg (single 
dose) 
NS 25.8 - - - - - 
Up to 30 5 mg            
(5 x 1 mg)  
NS 66.0 - - - - - 
Glass Fibre 100/475 
Cullen  et al. 
2000a 
Glass fibre 
100/475 
 
IH 
7.5.12   
(12 month 
follow-up) 
>0.4, < 
20 
<0.1, 
<0.9 
1000 fibres/ 
cm
-3
 (single 
dose) 
0 NS - 10.5 - No NS 
Glass fibre 
100/475 
 
IP 
24 
10
9
 WHO 
fibres (single 
dose) 
33 NS - - - - NS 
E Glass 
Cullen  et al. 
2000a 
E Glass 
microfiber 
7.5.12 (12 
month 
>0.4, 
<20 
<0.1,  
<0.9 
1000 fibres/ 
cm
-3
 
4.7 - 16.2 6.9 - Yes 23.2 
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104E 
 
IH 
follow-up) 
E Glass 
microfiber 
104E 
 
IP 
24 
10
9
 WHO 
fibres (single 
dose) 
87.5 NS - - - - - 
Refractory Ceramic Fibres 
Smith et al. 
1987 
Ceramic wool 
Fiberfrax 
 
IH (rat) 
6.5.24 
(follow-up  
for life) 
25 1.8 
200 
fibres/cm
-3 
12 mg m
-3 SD
 
0 - - - 2 
Yes  
(22) 
0 
Ceramic wool 
Fiberfrax 
 
IH (Hamster) 
6.5.24 
(follow-up  
for life) 
25 1.8 
200 
fibres/cm
-3 
12 mg m
-3 SD
 
1 - - - 3 
Yes 
(1) 
0 
Ceramic wool 
Fiberfrax 
 
IT (rat) 
 
 
assessed 
for life 25 1.8 
10 mg 
SD
              
(2 x 5 mg) 
- - - - 27 
Yes  
(9) 
0 
Ceramic wool 
Fiberfrax 
 
IP (rat) 
 
 
assessed 
for life 25  
 
1.8 
 
25 mg 
SD
 
(single dose) 
83  NS - - - 
Yes  
(100) 
NS 
Pott et al. 
1987 
Ceramic wool, 
Fiberfrax 
 
IP 
Up to 30 
8.3 0.91 
45 mg               
(5 x 9 mg) 
NS 68.1 - - - - - 
Hesterberg 
et al. 1995 
RCF1 
 
IH (rat) 
6.5.24 
0 - > 100 0 - >3 30 mg m
-3 SD
 1.6 1.6 NS NS NS Yes 13 
RCF1 
 
IH (Hamster) 
6.5.18 
0 - > 100 0 - >3 30 mg m
-3 SD
 41 41 NS NS NS Yes 0 
Mast et al., 
1995a 
RCF1 
(Kaolin based) 
6.5.24 
 
12.8 – 
17.4 
0.8 
30 mg m
-3
 
(187 WHO 
1.6 1.6 Yes Yes NS Yes 
13 
(bronchoal
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IH  
(Up to 6 
months 
follow-up) 
fibres/cm
-
3
)
SD
 
veolar 
adenoma 
and 
carcinoma 
combined) 
RCF2 (alumina 
zirconia silica) 
IH 
6.5.24 
 
(Up to 6 
months 
follow-up) 
30 mg m
-3
 
(220 WHO 
fibres/cm
-3
)
 
SD
 
2.5 2.5 Yes Yes NS Yes 
7.4 
(bronchoal
veolar 
adenoma 
and 
carcinoma 
combined) 
RCF3  
(high purity) 
IH 
6.5.24 
 
(Up to 6 
months 
follow-up) 
30 mg m
-3
 
(182 WHO 
fibres/cm
-3
)
 
SD
 
1.7 1.7 Yes Yes NS Yes 
10.7 
(bronchoal
veolar 
adenoma 
and 
carcinoma 
combined) 
Mast et al., 
1995b 
RCF1 
(Kaolin based) 
IH 
6.5.24 
(Up to 6 
months 
follow-up) 
20 1 
3 mg m
-3
 
(36 WHO 
fibres/cm
-3
)
 
SD
 
0 0 Yes Yes NS No 
1.6 
(bronchoal
veolar 
adenoma 
and 
carcinoma 
combined) 
6.5.24 
(Up to 6 
months 
follow-up) 
9 mg m
-3
 
(91 WHO 
fibres/cm
-3
)
 
SD
 
0.8 0.8 Yes Yes NS Yes 
3.9 
(bronchoal
veolar 
adenoma 
and 
carcinoma 
combined) 
6.5.24 
(Up to 6 
months 
follow-up) 
16 mg m
-3
 
(162 WHO 
fibres/cm
-3
)
 
SD
 
0 0 Yes Yes NS Yes 1.6 
Bellmann et 
al. 2001 
RCF1 
 
IH 
6.5.3wk  
 
(12 month 
10.5 0.94 
51.2 mg m
-3 
SD
 
- - - - - 
Yes          
(5  
within 
NS 
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follow-up) 12 
months) 
RCF1a 
 
IH 
6.5.3wk  
 
(12 month 
follow-up) 
13.3 0.86 
25.8 mg m
-3 
SD
 
- - - - - 
Yes          
(8 
within 
12 
months) 
NS 
Titanium Dioxide 
Lee et al. 
1986 
Titanium 
dioxide 
(rutile) 
 
IH 
6.5.24 
- 
Aero-
diam 
1.5 – 
1.7 
10 mg - - 0.7 0.7 95.2 
Yes       
(7.5) 
NS 
6.5.24 
50 mg - - 0 0.7 100 
Yes    
(60.4) 
NS 
6.5.24 
250 mg - - 9.3 16.6 100 
Yes  
(98.7) 
NS 
Donaldson 
et al. 1988 
Titanium 
dioxide          
(rutile) 
 
IH 
7.5.15(wk) 
 
(up to 2 
months 
follow-up) 
- - 10 mg - - - - - 
No     
(after 3 
months) 
- 
Cullen et al. 
2000b 
Titanium 
dioxide 
(rutile) 
 
IH 
7.5.8 
- 
 
Aero-
diam 
2.1 
(±2.2) 
 
25 mg - - - - - 
No     
(after 7 
months) 
- 
7.5.8 
50 mg - - - - - 
No     
(after 7 
months) 
- 
Pott and 
Roller 2005 
Titanium 
dioxide P25 
hydrophilic 
(anatase) 
 
IT 
28 
- 0.025 
5 x 3 mg - - NS NS NS NS 52.4 
28 
5 x 6 mg - - NS NS NS NS 67.4 
28 
10 x 6 mg - - NS NS NS NS 69.6 
Pott and 
Roller 2005 
Titanium 
dioxide P805, 
AL 90, 
hydrophobic 
 
IT 
28 
- 0.021 
10 x 6 mg - - NS NS NS NS 0 
28 
20 x 6 mg - - NS NS NS NS 6.7 
Pott and Titanium 
28 
- 0.2 10 x 6 mg - - NS NS NS NS 29.5 
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Roller 2005 dioxide AL 23 
203-3 
hydrophilic 
(anatase) 
 
IT 
28 
20 x 6 mg - - NS NS NS NS 63.6 
Pott et al. 
1987 
Titanium 
dioxide 
(anatase) 
 
IP 
Up to 30 
granular 
10 mg         
(over 3 inj.) 
NS 0 - - - - - 
Up to 30 90 mg        
(over 5 inj.) 
NS 5.3 - - - - - 
Up to 30 100 mg     
(5x20 mg) 
NS 9.4 - - - - - 
Muhle et al. 
1987 
Titanium 
dioxide 
(anatase) 
 
IP 
24 
granular 
10 mg 
(single dose) 
NS 9.4 - - - - - 
Silicon Carbide 
Adachi et al. 
2001 
 
 
 
Silicon carbide 
whiskers 
 
IP 
24 
6.4 ±  
2.45 
0.3 ± 
1.58  
5mg (5 x 1 
mg) 
 
414 x 10
3
 
fibres/µg  
 
70  70 - - - - - 
 
24 
10mg (10 x 1 
mg) 
100  
(within 12 
months) 
100 - - - - - 
Johnson 
and Hahn, 
1996 
 
Silicon carbide 
– granular 
 
IP 
Assessed 
for life 
4.5 
(± 0.23) 
<1 
5.6×108 
fibres/kg bw 
SD
 
 
90 - - - - - - 
Assessed 
for life 
20.1 (± 
1.01) <1 
1.2×107 
fibres/kg bw 
SD
 
87 - - - - - - 
Assessed 
for life 
6.6 (± 
0.40) <1 
8×108 
fibres/kg bw
 
SD
 
23 - - - - - - 
Davis et al., 
1996 
Silicon carbide 
whiskers 
Assessed 
for life 
5 - 20 0.45 
1000 fibres/ 
cm
-3
 
10 20 - - - Yes NS 
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IH 
Akiyama et 
al.,2007 
Silicon carbide 
whiskers 
 
IH 
6.5.12 
 
(12 
months 
foloow-
up) 
2.8 ± 2.3  
0.5 ± 
1.5  
(Aero-
dynami
c 
diamet
er 2.4 ± 
2.4)  
 
2.6 (± 0.4) 
mg m
-3
  
(98 ± 19 
fibres/cm
-3
) 
- - - - 4.7 
Yes 
(severe) 
NS 
Potassium Octatitanate 
Yamato et 
al. 2003 
PT1 
potassium 
octatitanate 
whiskers 
 
IH 
 
 
6.5.12 
(12 
months 
follow-up) 
3.4 ± 2.7  
 
0.44 ± 
1.4  
 
2.2 ± 0.7 mg 
m
-3
  
(111 ± 34 
fibre/cm-
3
) 
- - - 10 - 
Yes   
(mild) 
NS 
Ikegami et 
al. 2004 
potassium 
octatitanate 
fibres 
 
IH 
6.5.24 
>5 <3 
200 WHO 
fibers/ cm-
3
 
- - - - - 
Yes  
(mild) 
NS 
Adachi et al. 
2001 
 
Potassium 
Octatitanate 
(whiskers) 
 
IP 
24 
6 ± 2.04  
0.35 ± 
1.51  
5 mg (5 x 1 
mg) 
 
594 x 10
3
 
fibres/µg  
20 NS - - - - - 
24 10 mg (10x 1 
mg) 
77 NS - - - - - 
Quartz 
Pott and 
Roller 2005 
Quartz 
 
IT 
28 
granular 
5 mg - - NS NS NS NS 65.7 
 
10 mg - - NS NS NS NS 71.4 
28 
10 x 2mg - - NS NS NS NS 77.8 
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Pott et al. 
1987 
Quartz 
(DQ12) 
 
IP 
 
Up to 30 
granular 
10 mg 
(single dose) 
NS 5.9 - - - - - 
Up to 30 
40 mg      
(2x20 mg) 
NS 22.0 - - - - - 
Kevlar 
Lee et al. 
1988 
Kevlar 
 
IH 
6.5.24 
< 100 < 3 
0.08 (± 0.04) 
mg 
2.4 (±0.8) 
fibrils/cm
-3 
SD
 
- - 0 0.7 0.7 No NS 
6.5.24 0.32 (± 0.08) 
25.5 (± 9.9) 
fibrils/cm
-3 
SD
 
- - 0 0.7 96.9 
Yes 
(93.9) 
NS 
6.5.24 0.63 (± 0.14) 
100 (± 37) 
fibrils/cm
-3 
SD
 
- - 2.9 2.9 98.5 
Yes 
(96.3) 
NS 
6.5.24 - (± 0.46) 
411 (± 109) 
fibrils/cm
-3 
SD
 
- - 7.6 7.6 93.5 
Yes 
(96.7) 
NS 
Warheit et 
al.  1994 
Kevlar 
Fibrils 
 
IH 
 
6.5.0  
(6 month 
follow-up) 
- 
Aero-
dynami
c 
diamet
er 3.2 
(±2.7) – 
4.7 
(±3.2) 
613 – 1344 
f/cm
-3
  
(2.9– 11.1 
mg m
-3
) 
- - - - - No - 
Pott et al. 
1987 
Kevlar 
 
IP 
Up to 30 
3.9 0.47 
20 mg
a 
(5x4mg) 
NS 5.8 - - - - - 
Polypropylene 
Hesterberg 
et al. 1992 
Polypropyl-
ene fibers 
 
IH 
6.5.3 
(up to 1 
month 
follow-up)  
11.6 – 
14.7 
1.2 
13.03 (± 
2.21) mg m
-3
  
(12.1 (± 3.5) 
fibers/ cm-
3
)  
- - - - - No - 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
44
 
6.5.3 (up 
to 1 
month 
follow-up) 
28.07 (± 
5.91) mg m
-3
 
(20.1 (± 7.1) 
fibres/ cm-
3
) 
- - - - - No - 
6.5.3 
(up to 1 
month 
follow-up) 
59.61 ± 6.46 
mg m
-3
 
(48.1 (± 
17.2) fibres/ 
cm-
3
) 
- - - - - No - 
Pott et al. 
1987 
Polypropyl-
ene fibers 
 
IP 
 
Up to 30  
7.4 1.1 
50 mg  
(5 x 10 mg) 
NS 2.0 - - - - - 
1
 Exposure durations are detailed to allow calculation of cumulative dose, if required. 
2
 For accuracy, exposure concentration is given as cited in original study. Should the reader wish to do so, calculations are available to convert gravimetric concentration to fibre 
number/cm
3
.  
3
 SD indicates that fibre size distribution data is included in the original citation 
4 percentage of rats examined with sarcoma, mesothelioma or carcinoma in the abdominal cavity (excluding tumours of the uterus) 
‘ – ‘ not applicable to study / not identified; NS – identified but numbers not specified; IH – inhalation; IP – intraperitoneal; IT – intratrachael; SD – standard deviation; Aero-diam – 
aerodynamic diameter ; HT – high aluminium/low silica type wool; WHO fibres are defined by the World Health Organization as having a length/diameter ratio ≥3, diameter <3 µm, and 
length >5 µm; a – non-homogeneous suspension. 
 689 
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7. Discussion and Conclusions  691 
Following review of all identified data, it is evident that, for a number of the fibres tested, the same 692 
or similar carcinogenic potential is exhibited whether inhalation and/or intratracheal, or 693 
intraperitoneal exposure models are used. The following fibres demonstrated consistently negative 694 
(or equivocally negative) results:  695 
• Wollastonite 696 
• 104/475 glass fibres 697 
• HT stone wool 698 
• Titanium dioxide, except at extremely high doses  699 
• Kevlar, notwithstanding a query about the relevance of certain tumours observed in an 700 
inhalation study 701 
• Polypropylene 702 
 703 
Only for amosite, silicon carbide whiskers, E-Glass, and possibly crocidolite and quartz, were results 704 
consistently positive for both inhalation and intraperitoneal or intrapleural study methods. 705 
Crocidolite and quartz were also consistently positive in intratracheal studies. 706 
 707 
For other fibre types, markedly different results for carcinogenic potential were obtained with 708 
different exposure models. These included: 709 
• Chrysotile 710 
• MMVFs (various types) including specifically: 711 
o 100/475 glass fibres 712 
o 104E glass fibres 713 
o RCF4 714 
                                                          
4
 RCF has tested positive in inhalation and intraperitoneal tests, however there is uncertainty about the positive IH results 
because of concerns about overload resulting from the high doses used and high particulate to fibre ratio. 
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• Potassium octatitanate 715 
 716 
For silicon carbide, marked differences were noted in the results for whiskers and the granular form 717 
in the intraperitoneal studies. Whilst silicon carbide whiskers showed positive findings, the non-718 
fibrous granular form was negative. 719 
  720 
A number of important caveats apply in considering the results presented here. The majority of 721 
experiments reviewed here were on fibres rather than dusts, and tumour type/location is often 722 
different for dusts and fibres. Where the same fibre type has been used in more than one study, 723 
there is not always consistency of manufacturer/producer. This could mean that fibres with slightly 724 
different chemical compositions are being compared. Even with the same manufacturer, differences 725 
may still occur due to inter-batch variations. This issue was highlighted by Guldberg et al. (2002) who 726 
suggested that stone wool fibres cannot have a defined chemical composition, as variations will 727 
necessarily occur during the processing of raw materials.  This reasoning would apply to the majority 728 
of fibres that are produced from natural raw materials of variable composition.  Due to the lack of 729 
definitive chemical compositions, it is difficult to confidently compare the study results on the same 730 
fibre types, which in turn makes it problematic to definitively compare the results from studies using 731 
different exposure methods of the same fibres. Also, not all of the papers reviewed here included 732 
sufficient information on the chemical composition of the fibre test materials to allow a truly robust 733 
comparison of results. The same is true of fibre/particle size distribution data. There is also a 734 
problem with fibre nomenclature. For example, MMVF10 and 11 are glass fibres, but some studies 735 
refer to glass wool or different types of glass fibre, which may or may not be the same; it is difficult 736 
to confidently compare these studies without the specific chemical composition data to determine if 737 
they are indeed the same fibre type.  738 
 739 
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Finally, the issue of dose is problematic in an exercise such as this. The majority of intraperitoneal 740 
studies and some intratracheal studies use one single large dose (or a limited series of smaller 741 
doses), while in the inhalation studies exposure is to a low concentration extended over a longer 742 
period of time. As a result, doses are difficult to directly compare. In addition, lung overload can 743 
occur and can lead to false positives, as shown for example in the study reported by Lee et al. (1986) 744 
and implied for the RCF experiment by Mast (1995a).  This underlines the importance of determining 745 
a relevant and appropriate dose when designing studies, in order to be confident in the validity of 746 
the findings. The same argument no doubt applies to intrapleural/intraperitoneal testing where the 747 
basis and validity of the amount of material injected is subject to even greater uncertainty. In all 748 
examples, the question of relevance to human exposures remains a source of uncertainty.  749 
 750 
To summarise, for some of the dusts and fibres reviewed, there is conformity between the results of 751 
intraperitoneal and inhalation such that they are either consistently positive (a few only) or 752 
consistently negative. For the remaining dusts and fibres reviewed, intraperitoneal and inhalation 753 
tests give different results, with positive results in the intraperitoneal test not being reflected by 754 
positive inhalation test results. In no circumstances was a positive inhalation study reflected by a 755 
negative intraperitoneal study. 756 
 757 
Intraperitoneal studies appear to be more ‘sensitive’ to the carcinogenic potential of injected 758 
materials, but as noted earlier this is a highly non-physiological route of exposure and false positive 759 
results cannot be discounted. As shown in this paper, positive IP/IPl study results for carcinogenicity 760 
are not consistently reflected by positive results in inhalation studies.  761 
 762 
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The German Committee on Hazardous Substances (AGS) document ‘ERR (exposure-risk relationship) 763 
for aluminium silicate fibres5’ makes the assumption that IP tests are able to accurately and in a 764 
quantitative fashion discriminate fibres in relation to their carcinogenic potency in the lung. As a 765 
consequence the AGS reaches the conclusion that certain types of MMMF pose a carcinogenic risk 766 
the same order of magnitude as crocidolite asbestos (Harrison et al., 2015). For the application of 767 
animal test results to human cancer risk assessment, it is very important to understand the strengths 768 
and weaknesses of the different methods used and the consistency or otherwise of the results 769 
obtained. Pott (1991) argued that while the inhalation method was the best to use for 770 
carcinogenicity testing of airborne particles, this is not the case in relation to respirable fibres and 771 
that false negatives should be expected. In line with this argument, Wardenbach et al. (2000) 772 
expressed reservations about the results obtained with asbestos in rodent inhalation studies 773 
compared to the human experience. Pott recommended that intratracheal, intrapleural and 774 
intraperitoneal instillation rather than inhalation should be used to determine the carcinogenicity of 775 
respirable fibres (Pott, 1991; Pott et al., 1992). However, the opposite view has been expressed by 776 
many researchers. For example,  Lippmann (2014), noting the findings of a review by Hesterberg and 777 
Hart (2001) which showed that positive results for carcinogenicity with a number of MMVF in 778 
injection/instillation studies were not replicated in well-conducted inhalation tests, concluded that 779 
“implantation studies are not appropriate for assessing the potential hazard of SVFs in humans 780 
exposed by inhalation”. This is in line with the conclusions by McClellan et al. (1992) regarding the 781 
superiority of inhalation testing. 782 
 783 
From the results of this survey it may be concluded that the intraperitoneal test can be used to 784 
exonerate a dust or fibre (because if negative in the intraperitoneal test it is extremely unlikely to be 785 
                                                          
5
 Exposure-risk relationship for aluminium fibres. Committee on Hazardous Substances (AGS) - AGS Management - BAuA - 
www.baua.de. May 2010. 
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positive in either inhalation or intratracheal tests)6 but it should not be used to determine that a 786 
dust or fibre would be carcinogenic by inhalation (Bernstein et al., 2001b). We would argue against 787 
the use of intraperitoneal tests for human health risk assessment except perhaps for the purpose of 788 
exoneration of a material from classification as a carcinogen.  789 
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 This is in line with an earlier statement by Pott et al. (1987) that “…if a high dose [of a dust] does not induce tumours in 
[the intraperitoneal] test, no suspicion of carcinogenic potency can be substantiated”. 
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A comparison of the results from intra-pleural and intra-peritoneal studies 
with those from inhalation and intratracheal tests for the assessment of 
pulmonary responses to inhalable dusts and fibres. 
Gail Drummond, Ruth Bevan, Paul Harrison  
Highlights 
• Comparison of findings from inhalation, intraperitoneal and intrapleural assays. 
• Focus on fibrous and particulate materials.  
• Assessment of the prediction of carcinogenicity using IT/IP studies.   
• It is suggested that IP studies can only be used to exonerate a dust or fibre. 
• Carcinogenicity of these should not be positively identified using IP studies.  
 
